OncoLab Co., Ltd. has been awarded the Korea Invention Promotion Association (KIPA) Chairman’s Award at the 2025 Intellectual Property Startup Competition, hosted by the Korean Intellectual Property Office (KIPO) and organized by KIPA. The award recognizes OncoLab’s outstanding innovation and excellence in intellectual property-driven biotechnology research and development.
 

Our proprietary ANGel platform integrates antibody conjugation with precision drug formulation and delivery, enabling targeted and sustained therapeutic activity at tumor sites. The award acknowledges the company’s pioneering role in bridging immunotherapy and precision drug delivery, and its strong potential for clinical and commercial application.

Dr. Jongseong Kim, Founder and CEO of OncoLab, stated:
“This award reflects OncoLab’s scientific and technological leadership built upon a strong intellectual property foundation. We will continue to accelerate clinical development and global partnerships for the ANGel platform to enhance therapeutic options for patients and contribute to a sustainable biotech innovation ecosystem.”

OncoLab plans to further strengthen its R&D and regulatory capabilities while expanding international collaborations for joint development and technology licensing opportunities.